IMCD (IMCD) Q2 2024 earnings summary

Executive summary

• Revenue for H1 2024 reached €2.385 billion, up 4% year-over-year, with operating EBITDA/EBITA at €270 million, reflecting a 2% decrease on a constant currency basis due to a weak Q1 but a strong Q2 recovery, mainly driven by acquisitions.

• Gross profit rose 4% to €607 million (+5% constant currency), while net result declined 7% to €141 million; cash EPS was €3.23, down 1-2%.

• Eleven acquisitions were completed year-to-date, expanding presence in key markets and adding approximately €250 million in revenue and 360 employees.

• Life sciences and industrials contributed €1.2 billion and €1.1 billion in revenue, respectively, with personal care (excluding China) and coatings/construction performing well, while food, nutrition, and pharma lagged.

• Market volatility and limited visibility persist, with management confident in the business model's resilience and further global expansion opportunities.

Financial highlights

• Forex-adjusted revenue increased 5% year-over-year, combining a 4% organic decline with a 9% boost from acquisitions.

• Gross profit margin held steady at 25.4% for H1 2024, nearly flat versus last year.

• Operating EBITDA/EBITA margin declined to 11.3% from 12.2% in H1 2023; conversion margin fell to 44.5% from 48.1%.

• Free cash flow was €221 million, down from €241 million in H1 2023, mainly due to higher working capital investment.

• Net debt increased to €1.59 billion, with a leverage ratio of 2.9x EBITDA.

Outlook and guidance

• Management remains confident in delivering further growth and efficiencies through investments in digital, commercial excellence, and operational improvements, but macroeconomic and political uncertainty make future demand difficult to predict.

• Opportunities exist for global expansion both organically and via acquisitions, though political instability and customer inventory caution continue to limit predictability.